[
    [
        {
            "time": "",
            "original_text": "安图生物(603658)：业绩整体稳健 为后续试剂销售打好基础",
            "features": {
                "keywords": [
                    "安图生物",
                    "业绩稳健",
                    "试剂销售"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安图生物(603658)：业绩整体稳健 为后续试剂销售打好基础",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药2021年度策略：不畏浮云遮望眼",
            "features": {
                "keywords": [
                    "医药",
                    "年度策略",
                    "展望"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药2021年度策略：不畏浮云遮望眼",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "医药行业2021年投资策略：“双循环”背景下 “创新升级＋进口替代”引领医药大时代",
            "features": {
                "keywords": [
                    "医药行业",
                    "双循环",
                    "创新升级",
                    "进口替代"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2021年投资策略：“双循环”背景下 “创新升级＋进口替代”引领医药大时代",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 5,
                "Duration": 9,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 4,
                "Headline_Structure": 9,
                "Source_Recency": 3
            }
        }
    ]
]